Research

GLADIATOR

GLADIATOR UC study This study is currently assessing an investigational drug for people with moderately active UC. Recruitment to this study is closed.   Stay tuned for more information!    

CULTIVATE

Do you have Crohn’s disease (CD)? The CULTIVATE team is looking for people with CD to join a clinical research study assessing an investigational drug. Why participate? ✔ Potentially get access to the oral, once-daily, investigational drug at no cost ✔ Be monitored by gastrointestinal (GI) specialists ✔ Feel empowered ✔ Help advance CD research Who can participate? You may be...

The Yellowstone Crohn’s Disease Clinical Research Program

The YELLOWSTONE Program is a series of Phase 3 clinical studies for people with moderately to severely active Crohn’s disease. These studies will evaluate the safety and effectiveness of an oral investigational study drug (ozanimod) which is taken once daily. Ozanimod is not a biologic, injection or infusion. Ozanimod is an immune regulator designed to change the body’s immune system response (...

OPTIMISE Study

Is there a better way to optimise disease control for patients with ulcerative colitis? A new study aims to find out Achieving and maintaining effective control of ulcerative colitis is the goal of treatment, but, as all patients know, it can be a challenge.  Current management of mild-to-moderate ulcerative colitis is typically guided by symptoms, with therapy increased during a flare and...

Discover the true effect of anaemia in IBD

The new AEGIS-1, and AEGIS-2 studies are aiming to find out whether ST10-021, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in non-active ulcerative colitis (UC), and non-active Crohn’s disease (CD). Summary For people with ulcerative colitis (UC) or Crohn’s disease (CD), iron deficiency anaemia (IDA) is a common problem. Symptoms...

TRAFFIC Study

The primary objective of the TRAFFIC clinical research studies is to find out if the investigational medicine being studied is effective in reducing the severity of the symptoms to the point of remission in individuals with moderate to severe ulcerative colitis or Crohn’s disease when compared to placebo. The secondary objective is to evaluate if the investigational medicine being studied is...

COVID-19 IBD patients' perception

The current state of emergency related to the coronavirus (COVID-19) pandemic represents a difficult period for both patients and doctors, as we face a new enemy, of which little or nothing is known, and which requires everyone's collaboration to overcome the problem. For this reason, EFCCA has conducted a survey in order to better understand the concerns and fears of patients with...